Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30635458 | 0.95 | HRH3 (0.54) | HRH3TSHRPOLBALDH1A1MAPK1 | |
| SCHEMBL30635452 | 0.88 | HRH3 (0.52) | HRH3ALDH1A1KDM4E | |
| SCHEMBL25177979 | 0.81 | TAAR1 (0.55) | HRH3ALDH1A1KDM4E | |
| SCHEMBL24571880 | 0.79 | HRH3 (0.68) | HRH3TSHRALDH1A1HPGD | |
| SCHEMBL30635456 | 0.77 | HRH3 (0.47) | HRH3POLBKDM4E | |
| SCHEMBL27319365 | 0.77 | MYLK4 (0.48) | HRH3TSHRALDH1A1MAPK1HPGD | |
| SCHEMBL8191281 | 0.76 | POLB (0.57) | TSHRPOLBALDH1A1MAPK1AOC3 | |
| SCHEMBL10272665 | 0.76 | POLB (0.53) | TSHRPOLBALDH1A1MAPK1AOC3 | |
| SCHEMBL15260468 | 0.76 | HRH3 (0.56) | HRH3TSHRALDH1A1 | |
| SCHEMBL14606256 | 0.76 | HRH3 (0.52) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | HRH3 4782/4885TSHR 4128/4885POLB 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.